Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulse sequence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Pulse sequence. Displaying page 1 of 1.
    EudraCT Number: 2015-001501-14 Sponsor Protocol Number: 2013/142/HP Start Date*: 2016-02-26
    Sponsor Name:Rouen University Hospital
    Full Title: Pilot study of aprepitant effect on aldosterone secretion in diabetic patient (diabetes mellitus) with hypertension associated with low renin
    Medical condition: Diabetic patient (diabetes mellitus) with hypertension associated with low renin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10052741 Endocrine and metabolic secondary hypertension HLT
    18.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004728-11 Sponsor Protocol Number: MR/EUM202 Start Date*: 2005-03-25
    Sponsor Name:Avera Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patien...
    Medical condition: Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023311-34 Sponsor Protocol Number: CPA 368-10 Start Date*: 2011-02-04
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol...
    Medical condition: healthy male and female volunteers, intended for the treatment of dobutamine-induced tachycardia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040752 Sinus tachycardia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-002782-34 Sponsor Protocol Number: B1871061 Start Date*: 2020-09-03
    Sponsor Name:Pfizer Inc.
    Full Title: A phase 1, open-label, randomized, 2-period, 2 sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants...
    Medical condition: Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082178 Philadelphia positive chronic myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003233-14 Sponsor Protocol Number: 18CH129 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Saint Etienne
    Full Title: Evaluation of the neonatal autonomic stress during intubations under Propofol in a population of premature infants under 33 w’GA
    Medical condition: population of premature infants under 33 w’GA requiring intubation for the administration of exogenous surfactant
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10003969 Baby premature LLT
    20.0 100000004855 10020477 Hyaline membrane disease LLT
    20.1 100000004852 10002321 Anesthesia LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023612-14 Sponsor Protocol Number: N/A Start Date*: 2013-03-08
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic reso...
    Medical condition: Marfan syndrome.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10026829 Marfan's syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008936-10 Sponsor Protocol Number: NIMINI-1/2 Start Date*: 2009-03-16
    Sponsor Name:Division of Cardiology, Robert-Bosch-Krankenhaus
    Full Title: Comparative evaluation of different CMR pulse-sequences with respect to their practicability and diagnostic performance in diagnosing the inflamed myocardium in patients with acute myocardial infar...
    Medical condition: Patients with acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000891 Acute myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004812-73 Sponsor Protocol Number: BP18-1-501 Start Date*: 2022-05-16
    Sponsor Name:Leiden University
    Full Title: The influence of pharmacological conditioning with S-ketamine on pain sensitivity in patients with Fibromyalgia Syndrome
    Medical condition: Fibromyalgia Syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001883-91 Sponsor Protocol Number: CLIN-60190-452 Start Date*: 2022-10-07
    Sponsor Name:Ipsen Bioscience Inc
    Full Title: A Phase I, Open Label, Randomised, Balanced, Single-dose, Two-period, Two-sequence Crossover-design Study to Evaluate Effects of Food on the Bioavailability of 80 mg Elafibranor (IPN60190) To-be-ma...
    Medical condition: This is a study to evaluate the effects of food on the bioavailability of elafibranor in healthy adult participants. It is part of a clinical development program for the IMP, the intended indicatio...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004871 10036680 Primary biliary cirrhosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004261-10 Sponsor Protocol Number: AR-105-002 Start Date*: 2017-10-19
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia
    Medical condition: Pseudomonas aeruginosa pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Completed) HU (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001641-79 Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003839-20 Sponsor Protocol Number: CVT5127 Start Date*: 2009-02-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography
    Medical condition: Suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002302-39 Sponsor Protocol Number: RSV-M-301 Start Date*: 2016-09-06
    Sponsor Name:Novavax, Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Alumi...
    Medical condition: Respiratory syncytial virus (RSV) is the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide. In industrialized countries, nearly all children have...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: In utero, Newborns, Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001653-40 Sponsor Protocol Number: 64041575RSV2003 Start Date*: 2016-12-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 09:59:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA